We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
MedImmune is looking into a potential sale of the company, as the board of directors authorized management to evaluate third-party interest in an acquisition that would provide a “better value” for its stockholders than continuing its business on a standalone basis.